SRT-1720 HCl – (1001645-58-4)

SRT-1720 is an experimental drug developed by Sirtris Pharmaceuticals, designed to activate the sirtuin subtype SIRT1. It is a small-molecule compound that has demonstrated significant potency, being 1000 times more effective than the well-known SIRT1 activator resveratrol.

In animal studies, SRT-1720 has shown promising results in improving insulin sensitivity and reducing plasma glucose levels in fat, muscle, and liver tissues. Additionally, it has been found to enhance mitochondrial and metabolic function.

A notable study conducted by the National Institute on Aging indicated that SRT-1720 could potentially extend the lifespan of obese mice by up to 44%. Despite these encouraging findings, the compound’s efficacy and safety in humans remain unestablished.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

SRT-1720 is an experimental drug developed by Sirtris Pharmaceuticals, designed to activate the sirtuin subtype SIRT1. It is a small-molecule compound that has demonstrated significant potency, being 1000 times more effective than the well-known SIRT1 activator resveratrol.

In animal studies, SRT-1720 has shown promising results in improving insulin sensitivity and reducing plasma glucose levels in fat, muscle, and liver tissues. Additionally, it has been found to enhance mitochondrial and metabolic function.

A notable study conducted by the National Institute on Aging indicated that SRT-1720 could potentially extend the lifespan of obese mice by up to 44%. Despite these encouraging findings, the compound’s efficacy and safety in humans remain unestablished.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/SRT-1720
https://pubchem.ncbi.nlm.nih.gov/compound/25232708
https://www.medchemexpress.com/srt-1720-hydrochloride-1.html
https://www.medkoo.com/products/32147
https://pmc.ncbi.nlm.nih.gov/articles/PMC9663539/
https://www.sciencedirect.com/science/article/pii/S0021925819644728

Other Names	SRT 1720 Hydrochloride, SRT1720 Hydrochloride
IUPAC Name	N-[2-[3-(piperazin-1-ylmethyl)imidazo[2, 1-b][1, 3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride
CAS	1001645-58-4
Molecular Weight	506
Molecular Formula	C25H24ClN7OS
SMILES	C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

Products

Consulting & Services

Check Out Our Research And Updates

SRT-1720 HCl – (1001645-58-4)

SRT-1720 is an experimental drug developed by Sirtris Pharmaceuticals, designed to activate the sirtuin subtype SIRT1. It is a small-molecule compound that has demonstrated significant potency, being 1000 times more effective than the well-known SIRT1 activator resveratrol.

In animal studies, SRT-1720 has shown promising results in improving insulin sensitivity and reducing plasma glucose levels in fat, muscle, and liver tissues. Additionally, it has been found to enhance mitochondrial and metabolic function.

A notable study conducted by the National Institute on Aging indicated that SRT-1720 could potentially extend the lifespan of obese mice by up to 44%. Despite these encouraging findings, the compound’s efficacy and safety in humans remain unestablished.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

SRT-1720 HCl – (1001645-58-4)

SRT-1720 is an experimental drug developed by Sirtris Pharmaceuticals, designed to activate the sirtuin subtype SIRT1. It is a small-molecule compound that has demonstrated significant potency, being 1000 times more effective than the well-known SIRT1 activator resveratrol.

In animal studies, SRT-1720 has shown promising results in improving insulin sensitivity and reducing plasma glucose levels in fat, muscle, and liver tissues. Additionally, it has been found to enhance mitochondrial and metabolic function.

A notable study conducted by the National Institute on Aging indicated that SRT-1720 could potentially extend the lifespan of obese mice by up to 44%. Despite these encouraging findings, the compound’s efficacy and safety in humans remain unestablished.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

Related products

Quick Contact